Hong Kong Island, Hong Kong, China Related Funds
| Fund Name | Location |
| Aretex Capital Partners | New York, New York, United States |
| CMHJ Partners | China, Shanghai |
| Converge Ventures | Hilliard, Ohio, United States |
| Counterpart Advisors | California, Manhattan Beach, United States |
| Gene Capital | Beijing, Beijing, China |
| Greenbridge Partners | Connecticut, Greenwich, United States |
| Gron Ventures | California, Newport Beach, United States |
| HealthInvest Equity Partners | Connecticut, Stamford, United States |
| J.P. Morgan Asset Management | New York, New York, United States |
| Levant Capital Limited | Dubai, United Arab Emirates |
| Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center | - |
| Propitious Capital | China, Shanghai |
| Provident Trust Group | Las Vegas, Nevada, United States |
| Rastar Capital | China, Guangdong, Guangzhou |
| Revelation Partners | California, San Francisco, United States |
| Shenzhen Shanhai Ventures | - |
| Shuimu Fund | - |
| Successful Entrepreneur Investors (SEI) | California, San Francisco, United States |
| Variant Alternative Income Fund | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
InnovHeart | $55M | 27 Jan 2022 | Milan, Lombardy, Italy | ||
Corisma | $27M | 30 Aug 2021 | Bethany, Connecticut, United States | ||
eTheRNA immunotherapies | $40M | 16 Jun 2020 | Belgium, Brussels-Capital | ||
Cloudbreak Therapeutics | $25M | 17 Apr 2020 | Irvine, California, United States |
– CoRISMA, a New Haven CT-based stage medical device company, raised $27M in Series A funding.
– The round was led by China Grand Pharmaceutical and Healthcare Holdings Limited.
– The company intends to use the funds to accelerate development and expand availability of the CoRISMA cardiac treatment device.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
InnovHeart | $55M | 27 Jan 2022 | Milan, Lombardy, Italy | ||
Corisma | $27M | 30 Aug 2021 | Bethany, Connecticut, United States | ||
eTheRNA immunotherapies | $40M | 16 Jun 2020 | Belgium, Brussels-Capital | ||
Cloudbreak Therapeutics | $25M | 17 Apr 2020 | Irvine, California, United States |
